[The influence of polypeptide liver complex and tetrapeptide KEDA on organism physiological function in norm and age-related pathology.].
Level 5 - mechanism / opinion, no new human data
Narrative review of in vitro and animal models with no human clinical data
What was done
This review evaluated published evidence on the hepatoprotective, immunomodulatory, and geroprotective effects of a calf liver polypeptide extract (Ventvil) and the synthetic tetrapeptide KEDA (Livagen; Lys-Glu-Asp-Ala). The summary covers findings across in vitro experiments and animal models of hepatic pathology, including acute hepatitis, chronic hepatitis, and liver cirrhosis/fibrosis.
What was found
The abstract provides no numerical data, effect sizes, or statistical metrics. Qualitatively, it states that Ventvil and KEDA demonstrated concordant therapeutic activity, normalized immune and antioxidant status, restored liver function in hepatitis models, and showed maximal protective effects in the context of aging.
Why it matters
Polypharmacy and aging increase vulnerability to liver injury in older populations. This synthesis highlights peptide-based complexes as potential therapeutic candidates for hepatoprotection and immunomodulation in age-associated hepatic disorders.
Limits
The source is a narrative review without reported systematic search methodology or human clinical trial data. Findings are limited to preclinical animal and in vitro models, and the abstract reports no specific sample sizes, dosing regimens, or quantitative outcome measures.
Cited by
- context Vladimir Khavinson identified specific peptides, such as Livagen and Ovagen, in liver tissue.